BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...

A Phase 2 clinical trial finds that ALT flares are common in hepatitis D patients treated with pegylated interferon-alpha, ...

Brii Biosciences has reported promising interim results from its Phase II ENSURE study of elebsiran, a hepatitis B ...

The global interferons market is on a steady growth trajectory, with its valuation projected to surge from USD 9.4 billion in 2022 to USD 13.8 billion by 2032. According to a recent report by Future ...

Learn how nanoparticles cross the blood-brain barrier (BBB) and explore their potential in treating neurological disorders ...

Serina Therapeutics (SER) announced that Randall Moreadith, CDO, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, ...

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...